Buy KLOW Blend Online

Product Details: KLOW Blend (BPC-157 + GHK-Cu + TB-500 + KPV)

What is KLOW Blend?

KLOW Blend is a four-peptide research formulation. It combines four distinct synthetic peptides in a single lyophilized vial. Each vial delivers 10mg of BPC-157, 50mg of GHK-Cu, 10mg of TB-500, and 10mg of KPV. Total delivery is 80mg per vial.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a stable fragment of a naturally occurring protein. This is commonly found in gastric juice. In preclinical models, it is studied to assess its influence on cellular signaling pathways involved in:

• Tissue remodeling
• Angiogenesis, and
• Nitric oxide modulation

GHK-Cu is a copper(II)-chelated tripeptide (glycyl-L-histidyl-L-lysine). It is a naturally occurring copper complex studied in laboratory settings for its role in connective-tissue and extracellular-matrix remodeling, processes central to the study of skin and wound-healing research in experimental models.

TB-500 is a synthetic fragment of Thymosin Beta-4. It comprises residues 17–23 and retains the actin-binding motif of the parent peptide. In laboratory settings, it is investigated for its role in actin dynamics and cell migration, processes central to the study of tissue repair in experimental models.

KPV is a synthetic tripeptide fragment (Lys-Pro-Val) derived from the C-terminal region of alpha-MSH. In laboratory settings, it is investigated for its role in inflammatory-signaling suppression via the NF-κB pathway, a process central to the study of inflammation in experimental models.

This lyophilized powder format is used in research settings as a delivery method that allows investigators to study combined tissue-repair and anti-inflammatory pathway engagement without preparing and mixing four separate vials.

Disclaimer: KLOW Blend is a research compound not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use. It is not intended to diagnose, treat, cure, or prevent any disease. This product is strictly for laboratory research purposes only.

ATTENTION: This product is strictly for LABORATORY AND RESEARCH PURPOSES ONLY. Not for human or veterinary use.

Mechanism of Action of KLOW Blend

BPC-157 Working in Preclinical Models

BPC-157 is thought to exert its effects in preclinical models primarily through modulation of the nitric oxide (NO) system and activation of growth factor signaling pathways. Specifically, experimental data suggest it interacts with VEGFR2 via Src-caveolin-1-eNOS and PI3K-Akt-eNOS axes. This is thought to affect angiogenic activity, fibroblast behavior, and collagen organization in tissue repair models.

Key mechanistic observations from laboratory studies:

• VEGF upregulation: BPC-157 is thought to upregulate VEGF expression, which can stimulate angiogenesis at sites of tissue disruption in animal models.
• ERK1/2 activation: Studies in preclinical settings have observed activation of extracellular signal-regulated kinases, which plays a role in cellular proliferation and survival.
• Nitric oxide modulation: BPC-157 is thought to interact with the NO pathway, influencing vascular tone and microvascular integrity.

GHK-Cu Working in Preclinical Models

GHK-Cu is thought to work primarily through copper-dependent stimulation of connective-tissue remodeling. It regulates fibroblast activity and extracellular matrix protein synthesis, directing collagen and elastin production in experimental wound-healing and skin models.

Key mechanistic observations from laboratory studies:

• Collagen and elastin synthesis: GHK-Cu is thought to stimulate collagen, elastin, and glycosaminoglycan synthesis via copper-dependent matrix remodeling.
• Fibroblast regulation: In vitro studies have observed GHK-Cu influencing fibroblast proliferation and activity in connective-tissue models.
• Copper-dependent mechanism: Preclinical data suggest GHK-Cu's activity depends on its chelated copper ion, distinct from receptor-mediated signaling.

TB-500 Working in Preclinical Models

TB-500 is thought to work primarily through the regulation of actin dynamics. It binds G-actin monomers with high affinity, sequestering monomeric actin and controlling its availability for polymerization. This process is central to cellular motility in experimental models as it directs the movement of cells during wound-closure assays.

Key mechanistic observations from laboratory studies:

• G-actin sequestration: TB-500 binds monomeric G-actin, regulating the pool available for filament polymerization.
• Cell migration: In vitro studies have observed TB-500 influencing the migration of keratinocytes, endothelial cells, and fibroblasts in wound models.
• Angiogenic signaling: TB-500 has been observed to stimulate endothelial cell migration and tube formation in in vitro angiogenesis assays.

KPV Working in Preclinical Models

KPV is thought to work primarily through inhibition of NF-κB signaling, a transcription-factor pathway associated with pro-inflammatory cytokine production. This process is central to inflammatory-response research in experimental models as it directs cytokine-expression endpoints.

Key mechanistic observations from laboratory studies:

• NF-κB pathway inhibition: KPV is thought to suppress NF-κB activation, reducing downstream pro-inflammatory cytokine expression.
• PepT1-mediated cellular uptake: KPV enters intestinal epithelial and immune cells via the PepT1 (SLC15A1) di/tripeptide transporter. Once intracellular, it is thought to inhibit NF-κB signaling by stabilizing IκB-α and blocking the interaction between the p65/RelA subunit and importin-α3, the carrier protein normally required for p65's nuclear translocation — a receptor-independent mechanism documented at nanomolar concentrations (Dalmasso et al. 2008, PMID 18061177).
• Cytokine modulation: In vitro and in vivo studies have observed KPV reducing markers of intestinal and tissue inflammation in animal models.
• Non-pigmentation mechanism: Despite its derivation from alpha-MSH, KPV does not bind melanocortin receptors and has no pigmentation-related activity.

Why combine BPC-157, GHK-Cu, TB-500, and KPV?

In laboratory settings, BPC-157, GHK-Cu, TB-500, and KPV are studied together because they are thought to operate through mechanistically distinct but potentially complementary pathways. BPC-157 is primarily investigated for its effects on angiogenic and NO-mediated signaling. GHK-Cu is studied for copper-dependent connective-tissue remodeling. TB-500 is studied for its role in actin-dependent cell migration. KPV is studied for its role in suppressing inflammatory signaling. Researchers use this combination to probe whether these four distinct pathways interact or produce additive effects in tissue-repair and anti-inflammatory research models.

Chemical Properties of KLOW Blend

BPC-157

Property	Detail
Molecular Formula	C62H98N16O22
Molecular Weight	1,419.5 g·mol⁻¹
CAS Number	137525-51-0
Purity	≥99% (HPLC verified, per batch COA)
Physical Form	White lyophilized powder
Storage	-20°C, protected from light and moisture
Classification	Research Use Only (RUO)

GHK-Cu

Property	Detail
Molecular Formula	C14H21CuN6O4
Molecular Weight	400.9 g/mol
CAS Number	89030-95-5
Purity	≥99% (HPLC verified, per batch COA)
Physical Form	White to pale blue lyophilized powder
Storage	-20°C, protected from light and moisture
Classification	Research Use Only (RUO)

TB-500

Property	Detail
Molecular Formula	C38H68N10O14
Molecular Weight	889.0 g/mol
CAS Number	885340-08-9
PubChem CID	62707662
Purity	≥99% (HPLC verified, per batch COA)
Physical Form	White lyophilized powder
Storage	-20°C, protected from light and moisture
Classification	Research Use Only (RUO)

KPV

Property	Detail
Molecular Formula	C16H30N4O4
Molecular Weight	342.43 g/mol
CAS Number	67727-97-3
Purity	≥99% (HPLC verified, per batch COA)
Physical Form	White lyophilized powder
Storage	-20°C, protected from light and moisture
Classification	Research Use Only (RUO)

Note: "TB-500" in this formulation refers to the synthetic 7-amino-acid fragment (residues 17–23) of Thymosin Beta-4, which retains the actin-binding motif of the parent peptide. This is a smaller molecule than the full-length 43-amino-acid Thymosin Beta-4; findings from full-length Tβ4 research cannot be assumed to apply directly to this fragment. KPV does not bind melanocortin receptors and has no pigmentation-related activity, despite being derived from the alpha-MSH sequence.

Blend Specification

Property	Detail
BPC-157 per vial	10 mg
GHK-Cu per vial	50 mg
TB-500 per vial	10 mg
KPV per vial	10 mg
Total per vial	80 mg
Format	Lyophilized powder, single vial
Origin	USA-made

Note on GHK-Cu quantity: In vitro fibroblast studies typically use GHK-Cu at nanomolar to low-micromolar concentrations. The larger 50mg mass per vial, relative to the other three components, reflects the working-solution volumes needed across repeated experimental sessions at these low per-experiment concentrations — it does not indicate a difference in relative research priority or potency between the four components.

Research Applications of KLOW Blend

1. Angiogenesis Pathway Research In preclinical models, BPC-157 has been investigated for its potential to upregulate VEGF expression and CD34 markers in muscle and tendon tissue research. This suggests involvement in neovascularization processes.
2. Connective Tissue & Matrix Remodeling Research GHK-Cu's copper-dependent stimulation of collagen, elastin, and glycosaminoglycan synthesis makes it a tool for investigating extracellular matrix remodeling in skin and wound-healing research models.
3. Cell Migration and Actin Dynamics Studies TB-500's high-affinity binding to G-actin makes it a tool for investigating how cytoskeletal regulation affects cell migration in wound-closure and tissue-remodeling assays.
4. Anti-Inflammatory Pathway Research KPV's suppression of NF-κB signaling, via PepT1-mediated cellular uptake, makes it a tool for investigating pro-inflammatory cytokine expression in tissue-inflammation research models, layered alongside the three tissue-repair mechanisms above.

Risk and Handling Precautions

Risk Tier: MODERATE

This rating reflects all four peptides' bioactive activity at angiogenic, matrix-remodeling, cytoskeletal, and inflammatory-signaling pathways in preclinical models, the absence of established human safety profiles for this specific four-peptide combination, and standard handling considerations for reconstituted lyophilized peptide blends. Researchers must observe the following precautions at all times.

Handling Precautions: KLOW Blend should be handled by trained laboratory personnel only. Use appropriate personal protective equipment (PPE) at all times, including gloves and eye protection. Avoid direct skin contact, inhalation, or accidental exposure during laboratory handling.

Exposure Risks: All four are research compounds with no approved safety profiles for human exposure as a combined formulation. No human toxicity data exists for this specific blend.

Storage: Store at -20°C in a dry, dark environment protected from light, heat, and moisture. Check the batch Certificate of Analysis for lot-specific guidance. Do not use it if the seal has been compromised.

Toxicity and Data Limitations: No chronic toxicity data exist for this blend. All findings are from short-duration preclinical models of the individual components, not from testing of this specific four-peptide co-blended formulation.

WADA Notice — BPC-157: BPC-157 is listed under WADA Section S0 (Non-Approved Substances) as a pharmacological substance not approved for human therapeutic use. Tested athletes should not handle or use this product.

WADA Notice — TB-500: TB-500 (a Thymosin Beta-4 fragment) falls under WADA Prohibited List Section S2.3 — growth factors and growth factor modulators affecting muscle, tendon, or ligament protein synthesis/degradation, vascularization, energy utilization, regenerative capacity, or fiber type switching. This is a more specific classification than BPC-157's S0 catch-all and is prohibited both in- and out-of-competition. Tested athletes should not handle or use this product.

FDA Regulatory Status — BPC-157: BPC-157 was removed from the FDA's 503A Category 2 restricted bulk drug substances list in April 2026. It is scheduled for review by the FDA's Pharmacy Compounding Advisory Committee (PCAC) on July 23–24, 2026, to evaluate whether it should be added to the 503A permitted-substances ("positive bulks") list for use by licensed compounding pharmacies under specific conditions. This process is distinct from, and does not constitute, FDA drug approval. BPC-157 remains unapproved for any human or veterinary therapeutic use, and this product is not a compounded drug — it is sold strictly for laboratory research.

Why Choose BehemothLabz for Research-Grade KLOW Blend?

BehemothLabz supplies KLOW Blend for laboratory and research purposes. Every batch is independently tested by third-party laboratories for purity and identity. A Certificate of Analysis is publicly available for each lot. BehemothLabz does not self-certify.

The compound is USA-made and held to research-grade standards. It is available strictly to qualified researchers for use in controlled laboratory environments.

BehemothLabz Disclaimer

ATTENTION: All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.

Please make sure you go through the Terms and Conditions and familiarize yourself with them, as it is important. Kindly research the scientific uses of this product before making any purchases. Make note that the packaging and labels of the product may differ from those shown on the website.

Buying the product means you agree to our Terms and Conditions. You can contact our customer service team at support@behemothlabz.com if you are not fully satisfied with the product.

KLOW Blend Research FAQs

Why combine four peptides instead of studying them separately? 

Combining BPC-157, GHK-Cu, TB-500, and KPV into one lyophilized vial lets researchers study their combined tissue-repair and anti-inflammatory pathway engagement without separately weighing, reconstituting, and mixing four individual compounds — reducing preparation variability between research sessions.

How does each peptide in KLOW Blend differ mechanistically? 

BPC-157 is primarily associated with angiogenic and nitric oxide signaling. GHK-Cu works through copper-dependent matrix remodeling. TB-500 operates through actin dynamics and cell migration. KPV suppresses NF-κB-mediated inflammatory signaling via PepT1-dependent cellular uptake. All four are mechanistically distinct peptides studied together for possible complementary effects.

What does each vial deliver? 

Each vial delivers 10mg of BPC-157, 50mg of GHK-Cu, 10mg of TB-500, and 10mg of KPV, for a combined 80mg total.

Is KLOW Blend approved for human use? 

No. None of the peptides in this blend are approved by the FDA for human or veterinary use as this co-blended formulation. No regulatory body has cleared this product for any health application. This product is for laboratory research only.

Is TB-500 the same as full-length Thymosin Beta-4? 

No. TB-500 in this formulation is a synthetic fragment of Thymosin Beta-4, comprising residues 17–23 and retaining the actin-binding motif of the parent peptide. Full-length Thymosin Beta-4 is a 43-amino-acid peptide. Research findings from full-length Tβ4 studies cannot be assumed to apply directly to the fragment.

How does KPV enter cells if it isn't receptor-mediated? 

KPV is taken up via the PepT1 (SLC15A1) transporter, a di/tripeptide carrier that is upregulated in inflamed tissue. This transporter-dependent entry, rather than melanocortin receptor binding, is the documented basis for KPV's intracellular NF-κB inhibition (Dalmasso et al. 2008, PMID 18061177).

Are any components of KLOW Blend prohibited for athletes? 

Yes. BPC-157 falls under WADA Section S0 (Non-Approved Substances) and TB-500 falls under WADA Section S2.3 (growth factors and growth factor modulators). Both are prohibited at all times, in and out of competition. See the Risk and Handling section for details.

What purity standard does BehemothLabz provide for this blend? 

Every batch is independently tested by third-party laboratories. All four peptides are verified at ≥99% purity by HPLC analysis. A Certificate of Analysis confirming purity and molecular identity is available per lot.

How should KLOW Blend be stored? 

Store at -20°C in a dry, dark environment protected from light, heat, and moisture. Check the batch Certificate of Analysis for lot-specific guidance. Do not use it if the seal has been compromised.

References

1. Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of Physiology and Pharmacology. 2009;60(Suppl 7):191–196. https://pubmed.ncbi.nlm.nih.gov/20388964/
2. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. https://pubmed.ncbi.nlm.nih.gov/29986520/
3. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. https://pubmed.ncbi.nlm.nih.gov/18061177/
4. National Center for Biotechnology Information. PubChem Compound Summary for CID 62707662, TB-500 (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln). https://pubchem.ncbi.nlm.nih.gov/compound/62707662

Please click here to access instructions on how to make a payment.

How to Pay